Sign in →

Test Code LAB551 Acute Hepatitis Panel

Additional Codes

AHP

Includes:

Hepatitis A Antibody IgM, Hepatitis B Core Antibody IgM, Hepatitis B Surface Antigen Screen and Hepatitis C Virus Antibody Screen

Collection:

Specimen: Blood

Container: Serum Separator or Plain Red Tube

Volume: 7 mL; Minimum 3 mL

 

Pediatric Collection:

Three Gold or Red microtainers filled to 600 uL.

Stability:

Once serum is separated from cells:

 

Ambient: 8 Hours

Refrigerated (preferred): 1 Week

Frozen: 2 Weeks

Turn Around Time (TAT):

STAT: 2 HOURS

Routine: 3 HOURS

Test Availability:

24 hours a day / 7 Days a week

Performing Laboratory Section:

Chemistry / UMC MAIN LABORATORY

Reference Interval:

Hepatitis A Antibody IgM:  Non-reactive

 

Hepatitis B Core Antibody IgM:   Non-reactive

 

Hepatitis B Surface Antigen Screen:   Non-reactive

 

Hepatitis C Virus Antibody Screen:   Non-reactive

 

Interpretive Data:

Hepatitis A Antibody, IgM

Patients with positive test results are reported by the Laboratory to the local Health Dept. Interpretation information is based on the Abbott product literature. Results by other assay methods cannot be used interchangeably with the Abbott assay values.
Result Interpretation
Nonreactive IgM anti-HAV not detected. Does not exclude the possibility of exposure to or infection with HAV. Levels of IgM anti-HAV may be below the cut-off in early infection.
Grayzone IgM antibodies to HAV may or may not be present. Patients exhibiting grayzone test results should be closely monitored by redrawing and retesting at approximately one week intervals.†
Reactive IgM anti-HAV detected. Presumptive evidence of HAV infection. A reactive IgM anti-HAV result does not rule out other hepatitis infections.

† Monitoring the level of IgM anti-HAV by redrawing and retesting at approximately one week intervals will distinguish rapidly rising IgM anti-HAV levels associated with early acute hepatitis A infection from gradually decreasing or unchanging IgM anti-HAV levels often associated with late acute stage of HAV infection.

 

Hepatitis B Core Antibody, IgM

Patients with positive test results are reported by the Laboratory to the local Health Dept. Interpretation information is based on the Abbott product literature. Results by other assay methods cannot be used interchangeably with the Abbott assay values.
Result Interpretation
Nonreactive IgM anti-HBc antibodies not detected. Does not exclude the possibility of expsoure to infection with HBV.
Grayzone Antibodies to IgM Anti-HBc may or may not be present. Patients with specimens exhibiting grayzone test results should be retested at approximately one-week intervals.*
Reactive Presumptive evidence of IgM anti-HBc.

*Monitoring the level of IgM anti-HBc by retesting at approximately one week intervals will distinguish rapidly rising IgM anti-HBc levels associated with early acute hepatitis B infection from gradually decreasing or unchanging IgM anti-HBc levels often associated with late acute stage of HBV infection, six to nine months from the appearance of HBsAg.

 

Hepatitis B Surface Antigen Screen

Interpretation information is based on the Abbott product literature. Results by other assay methods cannot be used interchangeably with the Abbott assay values.
Result Interpretation
Nonreactive Specimen considered negative for HBsAg.
Reactive Specimen considered repeatedly reactive; will be confirmed using the ALINITY HBsAg Qualitative Confirmatory assay.

 

Hepatitis C Virus Antibody Screen

Interpretation information is based on the Abbott product literature. Results by other assay methods cannot be used interchangeably with the Abbott assay values.
Result Interpretation
Nonreactive Antibodies to HCV not detected; does not exclude the possibility of exposure to HCV.
Equivocal Antibodies to HCV may or may not be present; a reflexive HCV RNA test will be performed on the specimen to determine infection status (current or resolved).
Reactive Presumptive evidence of antibodies to HCV; a reflexive HCV RNA test will be performed on the specimen to determine infection status (current or resolved).